SICO upgrades Hammadi, Mouwsat to ‘Buy’, remains ‘Neutral’ on Dallah

10/02/2019 Argaam

 

SICO Investment Bank upgraded its rating on Al Hammadi Company for Development and Investment, Mouwasat Medical Services Co., National Medical Care Co. (Care) and Middle East Healthcare Co. (Saudi German Hospital) from “Neutral” to “Buy”.

 

SICO also maintained a “Neutral” recommendation on Dallah Healthcare Co, the investment bank said in a report.

 

The Bahrain-based investment bank cut target prices of the Saudi healthcare companies, reviewing revenue as well as profit margins assumptions for 2019 and 2020 on lower number of patients.

 

Saudi healthcare providers Mouwasat and Care are SICO’s top picks in the industry.

 

“Care can capitalize on the expansions that were carried out in 2018 and Q1 2019, in addition to the profit margins’ potential rally due to pricing strategy and resource-efficiency policy,” SICO noted.

 

Mouwasat is the sole healthcare company which recorded a profit rise for the first nine months of 2019.

 

“The healthcare sector was the worst performer among other business divisions in the Kingdom, as corporate results were negatively surprising,” SICO added.

 

“Also, the decline in the patients’ number results in lower revenue and a slowdown in the new medical facilities, as the industry depends on expats,” the investment bank stated.

 

SICO’s recommendations on Saudi healthcare companies

 

Company

Recommendation

Target Price ( SAR)

 

Previous

Current

Previous

Current

 

Al Hammadi

Neutral

Buy

35

30

 

Dallah

Neutral

Neutral

105

75

 

Mouwsat

Neutral

Buy

105

90

 

Care

Neutral

Buy

65

55

 

Saudi German Hospital

Neutral

Buy

65

38

 

 

Comments {{getCommentCount()}}

Be the first to comment

loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.